Clinical Trial Update: Safety Of DAPAGLIFLOZIN (FORXIGA) in Patient With Type 2 Diabetes Mellitus (T2dm) In Vietnam From A Post-Marketing Surveillance Program

View source ↗

Summary

A completed post-marketing surveillance update reports safety outcomes for dapagliflozin (Forxiga) in patients with Type 2 diabetes mellitus in Vietnam.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Forxiga (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Safety Outcomes | Status: COMPLETED